MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
SCWorx Corp. EBITDA 2011-2026 | WORX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA SCWorx Corp.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.26 M | -1.45 M | - | -3.74 M | -6.02 M | -11.9 M | -3.31 M | -6.86 M | -4.51 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.26 M | -11.9 M | -4.88 M |
Quarterly EBITDA SCWorx Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | -539 K | -563 K | -766 K | - | -960 K | -1.24 M | -677 K | - | -2.01 M | -2.85 M | -1.15 M | - | -789 K | -2.3 M | -6.35 M | - | 173 K | -5.58 K | -97.9 K | - | -649 K | -1.31 M | -2.35 M | - | -595 K | -2.7 M | -117 K | - | -76.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 173 K | -6.35 M | -1.27 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Health information services industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
1.43 B | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
-40.7 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
148 M | - | - | $ 2.94 B | USA |
 |
Change Healthcare
CHNG
|
691 M | - | - | $ 9.03 B | USA |
 |
Accolade
ACCD
|
-38.6 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
-5.95 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
140 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
187 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
70.8 M | $ 3.97 | 3.39 % | $ 372 M | USA |
 |
Akerna Corp.
KERN
|
-6.57 M | - | - | $ 161 M | USA |
 |
Health Catalyst
HCAT
|
-28.4 M | $ 2.29 | -3.18 % | $ 138 M | USA |
 |
HealthStream
HSTM
|
62.5 M | $ 21.16 | -1.44 % | $ 643 M | USA |
 |
iCAD
ICAD
|
-6.03 M | - | - | $ 102 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
253 M | - | -10.39 % | $ 886 M | USA |
 |
HealthEquity
HQY
|
271 M | $ 84.44 | -2.3 % | $ 7.23 B | USA |
 |
American Well Corporation
AMWL
|
-185 M | $ 4.92 | -0.2 % | $ 73.8 M | USA |
 |
Schrödinger
SDGR
|
-203 M | $ 17.19 | -0.81 % | $ 1.25 B | USA |
 |
So-Young International
SY
|
-579 M | $ 2.99 | 0.51 % | $ 237 M |  China |
 |
MTBC
MTBC
|
23.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
10x Genomics
TXG
|
-230 M | $ 23.08 | -0.47 % | $ 2.7 B | USA |
 |
1Life Healthcare
ONEM
|
-197 M | - | - | $ 3.37 B | USA |
 |
GoodRx Holdings
GDRX
|
135 M | $ 2.58 | 0.19 % | $ 995 M | USA |
 |
OptimizeRx Corporation
OPRX
|
-24 M | $ 11.63 | -2.76 % | $ 199 M | USA |
 |
Omnicell
OMCL
|
82.6 M | $ 50.66 | -1.3 % | $ 2.33 B | USA |
 |
Premier
PINC
|
119 M | - | - | $ 2.33 B | USA |
 |
Progyny
PGNY
|
19 M | $ 24.98 | -0.08 % | $ 2.14 B | USA |
 |
Phreesia
PHR
|
-107 M | $ 15.79 | -0.03 % | $ 862 M | USA |
 |
R1 RCM
RCM
|
223 M | - | - | $ 3.81 B | USA |
 |
Zhongchao
ZCMD
|
-110 K | $ 0.43 | -5.26 % | $ 2.24 M | China |
 |
NantHealth
NH
|
-35.3 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
20.8 M | - | - | $ 1.6 B | USA |
 |
Signify Health
SGFY
|
63.3 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
-3.18 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
-658 M | $ 6.29 | -0.94 % | $ 1.07 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-45.6 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
435 M | $ 223.62 | -0.73 % | $ 35.9 B | USA |